Skip to main content

Drug Interactions between diflunisal and probenecid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

probenecid diflunisal

Applies to: probenecid and diflunisal

Probenecid may increase the pharmacologic and toxic effects of diflunisal in some patients by inhibition of hepatic metabolism and displacement from plasma protein-binding sites. Increased diflunisal concentrations may result. The clinical significance has not been reported. When these drugs are combined, patients should be observed for diflunisal toxicity such as nausea, vomiting, drowsiness, tinnitus, tachycardia, sweating, or confusion.

References (3)
  1. Diamond JS, Paolino JS (1973) "Evidence for a postsecretory reabsorptive site for uric acid in man." J Clin Invest, 52, p. 1491-9
  2. Regal RE (1987) "Aspirin and uricosurics: interaction revisited." Drug Intell Clin Pharm, 21, p. 219-20
  3. Macdonald JI, Wallace SM, Herman RJ, Verbeeck RK (1995) "Effect of propenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal." Eur J Clin Pharmacol, 47, p. 519-23

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer